Table 1.

Diagnostic characterization of the population: 88 samples from hematological malignant disorders (both myeloproliferative and lymphoproliferative); 37 samples with AML, 1 sample with MDS, 12 samples with ALL, 25 samples with lymphoma, and 15 samples with multiple myeloma; 8 samples from hematological benign disorders; 5 samples with TTP, 2 samples with RA, and 1 CDE sample.

Type of Disorder	Group of Diseases	Type of Disease	Subtype of Disease
HAEMATOLOGICAL MALIGNANT DISORDERS (N = 88)	Myeloproliferative diseases (N = 38)	Acute myeloid leukemia (AML) (N = 37)	Acute myeloid leukemia (non-APL) (N = 35) Acute promyelocytic leukemia (APL) (N = 2)
		Myelodysplastic syndromes (MDS) (N = 1)
	Lymphoproliferative diseases (N = 50)	Acute lymphoid leukemia (ALL) (N = 12)	Lymphoblastic leukemia B (ALL-B) (N = 5) Lymphoblastic leukemia T (ALL-T) (N = 2) Chronic Lymphatic Leukemia (CLL) (N = 1) Acute Lymphoblastic Leukemia (ALL) (N = 4)
		Lymphoma (N = 25)	Diffuse large cell B lymphoma (N = 4) Richter syndrome (N = 2) Lymphoblastic Lymphoma (N = 6) Burkitt’s lymphoma (N = 4) Hodgkin’s lymphoma (N = 6) Non-Hodgkin’s lymphoma (N = 3)
		Multiple myeloma (MM) (N = 13)
HAEMATOLOGICAL BENIGN DISORDERS (N = 8)		Thrombotic thrombocytopenic purpura (TTP) (N = 5)
		Reactive lymphadenitis (RA) (N = 2)
		Hematopoietic stem cell donors (CSE) (N = 1)